MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease

Ruikang Liu, Jeffrey L. Americo, Catherine A. Cotter, Patricia L. Earl, Noam Erez, Chen Peng, Bernard MossbioRxiv 2021 · DOI

TL;DR

This paper presents a novel Modified Vaccinia Ankara (MVA) virus-based vaccine candidate for SARS-CoV-2. The MVA-vectored vaccines effectively induced neutralizing antibodies and T-cell responses in mice, significantly protected against lethal SARS-CoV-2 infection, and prevented viral replication in the respiratory tract. This work highlights MVA as a promising platform for developing effective COVID-19 vaccines.

What Problem Does This Paper Address?

The COVID-19 pandemic necessitated the rapid development of effective vaccines. While various vaccine platforms have emerged, there's a continuous need to explore and validate alternative vectors that can elicit robust and protective immune responses. Modified Vaccinia Ankara (MVA) is a well-established, replication-deficient viral vector with a strong safety profile, making it an attractive candidate for vaccine development. However, prior to this study, there was a lack of reported animal protection studies for MVA-based SARS-CoV-2 vaccines, leaving a gap in understanding their efficacy in preventing disease and viral spread. This paper aims to address this by characterizing MVA vectors expressing SARS-CoV-2 spike (S) protein and evaluating their immunogenicity and protective efficacy in a relevant animal model.

Methods

The researchers engineered several recombinant MVA (rMVA) vectors expressing modified versions of the SARS-CoV-2 S protein. These modifications included:

  • Proline substitutions (2P): To stabilize the prefusion conformation of the S protein.
  • Furin cleavage site mutations (Δfurin): To prevent S protein cleavage, which can affect its immunogenicity.
  • Deletion of endoplasmic reticulum retrieval signal (ΔERRS): To enhance surface expression.
  • Receptor Binding Domain (RBD) construct: Expressing only the RBD, anchored to the membrane.
  • D614G mutation: Incorporating a common mutation found in circulating SARS-CoV-2 strains.

These rMVAs were constructed using standard recombinant DNA techniques and plaque purification. Expression of the S proteins was confirmed in HeLa cells using Western blotting and flow cytometry. Immunogenicity was assessed in BALB/c mice by measuring S-binding antibodies via ELISA and neutralizing antibodies using a lentiviral pseudotype assay. T-cell responses were evaluated by stimulating splenocytes with S-derived peptides and measuring IFN-γ production. For protection studies, K18-hACE2 transgenic mice, known to be susceptible to SARS-CoV-2, were immunized with rMVAs and then challenged intranasally with live SARS-CoV-2. Outcomes measured included weight loss, survival, viral titers in lungs and nasal turbinates, and viral RNA levels.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and cell cultures.

Key Insights and Ideas

  • MVA as a Versatile SARS-CoV-2 Vaccine Platform: The study demonstrates that MVA can effectively express modified SARS-CoV-2 S proteins and elicit strong immune responses, validating its potential as a vaccine vector.
  • Structural Modifications Impact Immunogenicity: While many rMVA constructs showed comparable cell surface expression, subtle differences in modifications (like the furin cleavage site or RBD-only expression) might influence antibody and T-cell responses, though the paper notes little difference in overall antibody binding and neutralization across most constructs.
  • Robust Protection Against Lethal Challenge: Even a single vaccination with certain rMVAs provided significant protection against a lethal intranasal SARS-CoV-2 challenge in susceptible mice, preventing weight loss and death.
  • Prevention of Viral Replication: MVA vaccination effectively inhibited viral replication in both the upper and lower respiratory tracts, suggesting a role in reducing transmission.
  • Th1-Biased Immune Response: Isotype analysis indicated that rMVAs induced a predominantly Th1-type immune response, which is generally considered beneficial for viral infections.

Key Results

  • Antibody Production: rMVAs expressing various forms of the S protein induced significant levels of S-binding and pseudovirus-neutralizing antibodies in mice after prime and boost vaccinations. Neutralizing titers reached high levels, comparable to those seen with mRNA vaccines.
  • T-Cell Response: rMVA vaccination stimulated CD8+ T cells producing IFN-γ, indicating a cellular immune response.
  • Protection from Lethal Disease: K18-hACE2 mice immunized with rMVAs (even with a single dose of some constructs) were protected from weight loss and death following intranasal SARS-CoV-2 challenge.
  • Viral Load Reduction: Infectious SARS-CoV-2 was undetectable in the lungs of rMVA-vaccinated mice, and significantly reduced in nasal turbinates, suggesting effective control of viral replication.
  • Abortive Replication: Detection of subgenomic viral RNA in turbinates on day 2 only, but not later, indicated that any replication that occurred was abortive in immunized animals.

Limitations and Future Work

  • Mouse Model Specificity: While K18-hACE2 mice are a useful model for severe disease, their specific susceptibility might not fully translate to human responses. Further studies in other animal models and eventually human clinical trials are necessary.
  • Duration of Immunity: The study focused on short-term protection. The duration of immunity induced by these MVA vaccines remains to be determined.
  • Route of Administration: While intramuscular administration showed significant protection, exploring other routes like intranasal delivery could potentially offer even greater protection against respiratory infections and reduce transmission. The authors suggest it would be of interest to determine if IN administration could prevent replication entirely.
  • Comparison with Other Vaccines: While comparisons are made to mRNA vaccines regarding neutralizing titers, a direct head-to-head comparison of protective efficacy in the same model would be valuable.
  • Optimizing Boosts: The study explored homologous and heterologous boosts. Further optimization of boost strategies, potentially considering the interval between vaccinations to overcome anti-vector immunity, could enhance responses.

Summary updated

Abstract

Replication-restricted modified vaccinia virus Ankara (MVA) is a licensed smallpox vaccine and numerous clinical studies investigating recombinant MVAs (rMVAs) as vectors for prevention of other infectious diseases have been completed or are in progress. Two rMVA COVID-19 vaccine trials are at an initial stage, though no animal protection studies have been reported. Here, we characterize rMVAs expressing the S protein of CoV-2. Modifications of full length S individually or in combination included two proline substitutions, mutations of the furin recognition site and deletion of the endoplasmic retrieval signal. Another rMVA in which the receptor binding domain (RBD) flanked by the signal peptide and transmembrane domains of S was also constructed. Each modified S protein was displayed on the surface of rMVA-infected human cells and was recognized by anti-RBD antibody and by soluble hACE2 receptor. Intramuscular injection of mice with the rMVAs induced S-binding and pseudovirus-neutralizing antibodies. Boosting occurred following a second homologous rMVA but was higher with adjuvanted purified RBD protein. Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice. One or two rMVA vaccinations also prevented recovery of infectious CoV-2 from the lungs. A low amount of virus was detected in the nasal turbinates of only one of eight rMVA-vaccinated mice on day 2 and none later. Detection of subgenomic mRNA in turbinates on day 2 only indicated that replication was abortive in immunized animals.
BibTeX
@misc{liu2021mva,
  author = {Ruikang Liu and Jeffrey L. Americo and Catherine A. Cotter and Patricia L. Earl and Noam Erez and Chen Peng and Bernard Moss},
  title = {{MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease}},
  year = {2021},
  doi = {10.1101/2020.12.30.424878},
  howpublished = {bioRxiv},
}
Figure